Six biologics to be fast tracked from MedImmune (AZ owned) through a separate company – Viela Bio
Inflammatory and auto-immune (incl neuromyelitis) – all rare diseases
They’ll make a fortune!
All because outside AZ core >>> oncology, respiratory and cardiovascular and metabolic disease (seems pretty broad to me!)
J&J situation with Actelion buyout where Idorsia was created to run early phase candidates wasn’t J&J decision the owner of Actelion kept them as part of deal!